$MGX News

Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

Metagenomi Q1 EPS $(0.61) Misses $(0.55) Estimate, Sales $1.248M Miss $5.925M Estimate

Metagenomi Reports Study Showing CRISPR Editing Efficiency; Findings Support Development of Deliverable Gene Editing Systems

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Metagenomi Therapeutics: Q4 Earnings Snapshot

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Metagenomi Therapeutics Q4 Earnings Assessment

Metagenomi Q4 EPS $(0.60) Beats $(0.62) Estimate, Sales $3.911M Miss $6.745M Estimate

Metagenomi Q4 EPS $(0.60) Beats $(0.62) Estimate, Sales $3.911M Miss $6.745M Estimate

Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Metagenomi Changes Name To Metagenomi Therapeutics

Trainium3 UltraServers Now Available: Enabling Customers to Train and Deploy AI Models Faster at Lower Cost

Amazon Launches New AI Chip While Teasing Future Tech Collaboration With Nvidia

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Metagenomi shares are trading lower. The company reported Q3 financial results.